Androgen Deprivation Therapy with Postprostatectomy Radiotherapy: For Whom and for How Long? (European Urology)

A role for hormone therapy in men receiving salvage radiotherapy (SRT) after radical prostatectomy is well established. RTOG 9601, a phase 3 randomised control trial, demonstrated an overall survival benefit for 24mo of bicalutamide in this setting, with a hazard ratio of 0.77 (95% confidence interval [CI] 0.59-0.99) [1]. The absolute survival benefit at 12yr was 5% (76% vs 71%). It is less clear how to select which men with biochemical failure could safely receive SRT alone and be spared the morbidity of additional hormone therapy.